The last thing we want is to potentially endanger patients
On a single August day in 2022, Australia recorded 133 Covid deaths — a number that passed quietly through the news cycle yet anchored a deeper argument about the nature of medical care itself. At stake was not merely who could dispense an antiviral, but who holds the knowledge necessary to do so safely, and whether speed and access can be reconciled with the kind of intimate, longitudinal understanding that medicine at its best requires. The debate between GPs and pharmacists reflected a tension as old as healthcare: the pull between reaching more people faster and ensuring that each person reached is truly seen.
- Australia's single-day toll of 133 Covid deaths underscored that the pandemic retained its lethal momentum, even as public attention had begun to drift elsewhere.
- The Pharmacy Guild's push to make antivirals available over the counter without a prescription created an urgent fault line within the medical community, pitting efficiency against safety.
- GPs warned that antivirals carry serious risks — dangerous drug interactions, contraindications, allergies — that only a doctor with a patient's full history could reliably catch.
- International comparisons to New Zealand's more permissive model were challenged as misleading, given fundamental differences in how each country trains pharmacists and classifies medicines.
- A parallel story sharpened the stakes: a nineteen-year-old Aboriginal man died in a West Australian prison from untreated rheumatic heart disease after a cardiology referral was never followed through, exposing how systemic failures in medical oversight cost lives.
- The debate remained unresolved, suspended between two legitimate imperatives — the urgency to treat quickly and the discipline to treat carefully.
Australia recorded 133 Covid deaths on August 10, 2022 — a number that arrived without ceremony, folded into the daily news, yet gave shape to a growing argument at the heart of Australian medicine. The question was deceptively simple: should Covid antivirals be available over the counter at pharmacies, or should a doctor's prescription remain required?
The Royal Australian College of General Practitioners said no to over-the-counter access, and its president Karen Price explained why. These drugs were powerful and genuinely life-saving, but they were not safe for everyone. Certain patients had conditions that made them dangerous. Others were on medications that would interact badly. The problem, Price argued, was not pharmacist competence — it was pharmacist context. A pharmacist sees a customer; a GP sees a patient they may have known for years, whose medical record, medication list, and personal vulnerabilities are part of an ongoing relationship. That knowledge, she said, was not a bureaucratic formality. It was the safety net.
Price also resisted the comparison to New Zealand, where over-the-counter access had been introduced. The two countries' healthcare systems, pharmacist training standards, and drug classification frameworks were different enough that the comparison obscured more than it revealed.
The pharmacists were not wrong to want faster access. Delays in treatment cost lives too. Both sides were arguing in good faith, and both had patients at the center of their case. The disagreement was about where the greater risk lay — in the slowness of the current system or in the gaps that a faster one might open.
That same day, a coroner's finding brought a different kind of medical failure into view. Mr Yeeda, a nineteen-year-old Aboriginal man, had died in a West Australian prison in 2018 from complications of rheumatic heart disease. A referral to a cardiologist had been made years earlier and never followed through. The coroner ruled his death preventable. Advocates pointed to a systemic failure to provide culturally appropriate, continuous care to Indigenous prisoners — a reminder that access to medicine is only part of the story. Someone also has to be paying attention.
The antiviral debate and Mr Yeeda's death were not the same story, but they rhymed. Both turned on the question of who is responsible for knowing a patient well enough to keep them safe — and what happens when that responsibility is diffuse, delayed, or simply dropped.
Australia woke on August 10 to a familiar toll: 133 people dead from Covid in a single day. The number arrived without fanfare, buried in the day's news cycle, a reminder that the pandemic had not finished its work. But the deaths framed a larger argument taking shape in Australian medicine—one about who should decide who gets treated, and how.
The Royal Australian College of General Practitioners had drawn a line. The Pharmacy Guild, representing Australia's chemists, had been pushing for Covid antiviral treatments to be dispensed over the counter, without a doctor's prescription. It was a reasonable ask on its surface: make the medicine easier to reach, faster to obtain. But the GPs saw danger in the shortcut.
Karen Price, the RACGP's president, acknowledged the stakes plainly. These oral antivirals could be the difference between someone recovering at home and someone ending up in hospital. They were critical tools. But they were not harmless. They carried risks, and those risks were not distributed equally across the population. Some patients had conditions that made the drugs unsafe for them. Some were taking other medications that would interact badly. Some had allergies or complications that only a doctor who knew their full medical history would catch.
Price's argument was structural. A GP has what a pharmacist, no matter how well-trained, typically does not: years of knowing a patient. The medical record. The conversation history. The context. When a person walks into a pharmacy and asks for an antiviral, the pharmacist sees a transaction. When that same person sits across from their GP, the doctor sees a life—its complications, its vulnerabilities, its particular shape. "GPs are the key to safely prescribing these treatments," Price said. "We have a strong and, in many cases, long-standing connection with our patients and we know their health history."
She also pushed back against the international comparisons that often drove policy. Yes, New Zealand had moved toward over-the-counter access. But New Zealand's primary care system was not Australia's. The training requirements for pharmacists differed. The way medicines were classified and regulated was not the same. "It's like comparing apples with oranges," Price said. The metaphor was blunt, but the point held: context matters. What worked in one country's healthcare architecture might not work in another's.
The tension was real and not easily resolved. The GPs were not arguing against access—they were arguing for caution, for the preservation of a gatekeeping role that they believed protected patients. The pharmacists were arguing for efficiency, for removing a bureaucratic step that delayed treatment. Both sides had patients in mind. Both sides believed they were right.
On the same day the 133 deaths were reported, another story of medical failure surfaced. An Aboriginal man, Mr Yeeda, had died in a West Australian prison in 2018 from complications of rheumatic heart disease. He was nineteen years old. A prison doctor had referred him to a cardiologist years earlier, but the referral was never acted on. The coroner found his death preventable. Advocates said the problem was systemic: Indigenous prisoners were not receiving culturally appropriate healthcare, and the systems that should have tracked their medical needs had failed. The lesson was different but related—that access to medicine, and the safety of medicine, depended on more than just the availability of a drug. It depended on who was paying attention, who knew the patient, who cared enough to follow through.
Australia's Covid death toll continued to climb. The question of how to treat it—who should prescribe, who should dispense, what safeguards should hold—remained unresolved. The debate would continue, shaped by the same tension that had defined the pandemic from the start: the need to act quickly against the need to act carefully, the desire to save lives against the risk of causing harm in the attempt to save them.
Citas Notables
GPs are the key to safely prescribing these treatments. We have a strong and, in many cases, long-standing connection with our patients and we know their health history.— Karen Price, RACGP president
These treatments can make the difference between someone suffering relatively minor effects or ending up in hospital. However, we must proceed with caution because the last thing we want to do is potentially endanger patients.— Karen Price, RACGP president
La Conversación del Hearth Otra perspectiva de la historia
Why do the GPs think pharmacists can't be trusted with this decision?
It's not about trust, exactly. It's about what a pharmacist sees versus what a GP knows. A pharmacist sees a customer asking for a drug. A GP sees a patient with a decade of medical history—allergies, other medications, conditions that might make an antiviral dangerous. That knowledge matters when the drug carries risks.
But couldn't a pharmacist just ask the right questions?
Maybe some could. But there's no guarantee. And the training requirements aren't standardized the way they are for GPs. The RACGP's point is that you can't replicate a long-standing relationship with a few screening questions at a counter.
So this is really about protecting the GP's role in the system?
Partly, yes. But it's also about the 133 people who died that day. Each one of them might have had conditions, drug interactions, complications that a careful prescriber would have caught. The GPs are saying: slow down, let us do our job, because the cost of getting it wrong is real.
What about the person who needs the drug today and can't see their GP for a week?
That's the tension the GPs aren't fully answering. They say access needs to improve, but they're not saying how. They're just saying over-the-counter isn't the way. It's a defensive position, not a solution.
Does this happen in other countries?
Yes, but the RACGP says you can't compare directly. New Zealand's healthcare system is different. So is its pharmacy training. The rules about what medicines can be sold without a prescription vary everywhere. What works in one place might not work in another.
So what happens next?
The debate continues. The Pharmacy Guild will keep pushing. The GPs will keep resisting. Meanwhile, people are dying, and the question of how to get them treatment faster—safely—remains unanswered.